Biocon has raised Rs 1070 crore through allotment of 1,07,000 unlisted, secured, rated, redeemable, non-convertible debentures (NCDs) of face value of Rs 1,00,000 each on private placement basis in 3 series. Date of maturity of the said NCDs will be on February 21, 2028.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
